• October 2012 - Chief Clinical Scientist Academy of Clinical Sciences & Laboratory Medicine, IRELAND
• October 2017 - Clinical Scientist, (Protected Title) HCPC ( UK )
• June 2016 - Clinical Scientist - Health Authority, Abu Dhabi License No : ( GT 16011 )
  

• Changing Trends in Substance Abuse ( 2013 -  2015 ): A research work presented at the 15th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology in Japan and published in the International Addiction Review journal, Oct. 2017
• Developed and optimized a method for the detection and quantification Buprenorphine and Nor-Buprenorphine in Blood and Urine (under publication)
• Developed and optimized a method for the detection of Psychoactive substances in urine as the preferred matrix
• Developed and optimized a method for the detection of Opiates in urine as the preferred matrix
• Developed and optimized a general screening method for the detection of drugs of abuse in urine
• Developed and optimized a method for the detection of Benzodiazepines in urine as the preferred matrix
• Responding to patients and drug trends: advancement and development of clinical toxicology services at the National Rehabilitation Centre, Abu Dhabi between 2013 – 2018
• The Gabapentinoids conundrum: “mind the Gabs (published)
• Diabetes and illicit drug use ( under publication )
• New Psychoactive Substances, Chemical chameleons that evade detection and legislation, published 2017
• Assessment of Alcohol Exposure: Testing for Ethylglucuronide (Etg), Ethylsulfate (Ets),PUBLISHED 2017
• Hepatitis C Infection among Intravenous Drug Users. “A”, Silent Disease in an Invisible Population, PUBLISHED 2017
• CARBOHYDRATE-CEFICIENT TRANSFERRIN, A SENSITIVE BIOMARKER FOR HEAVY ALCOHOL ABUSE PUBLISHED 2018
• Assessment of the Use of Point-Of-Care, Pregabalin Testing For Drug Monitoring, Compared to Gas Chromatography Mass-Spectrometry (Pilot Study ) Published 2018, in collaboration with King’s College London and Elliot Forensic Consultants, Birmingham, UK
• ILLICIT DRUGS ABUSE IS A CONTINUOUS  CHANGING SCENE; A STUDY OF DRUG ABUSE BETWEEN JAN. 2013  TO  31 DEC. 2018(  UNDER PUBLICATION)
• Developed and Validated a method for the detection and qualitative identification of seventy two (72) different illicit drugs by solid phase extraction and LC-MS/MS ( under publication)
• Elarabi, H., Hasan, N., Marsden, J., Radwan, D., Adem, A., Almamari, S., elrasheed, A., 2020. Therapeutic Drug Monitoring of Buprenorphine/Naloxone Treatment in Opioid Use Disorders: Clinical Feasibility and Optimising Assay Precision. Pharmacopsychiatry 53, 1–9 DOI:10.1055/a-1083-6842
• Elarabi, H., elrasheed, A., Ali, A. Shawky, M., Hasan, N., Gawad, T.A., Adem, A., Marsden, J., 2019. Suboxone Treatment and Recovery Trial (STAR-T): Study protocol for a randomised controlled trial of opioid medication assisted treatment with adjunctive medication management using therapeutic drug monitoring and contingency management. J Addict, https://doi.org/10.1155/2019/2491063
• Hesham Elarabi; Mansour Shawky; Nael Mustafa;Doaa Radwan; Abuelgasim ELrasheed; Ahmed Yousif Ali; Mona Osman , Ahmed Kashmar; Helal Al Kathiri; Tarek Gawad; Ayman Kodera; Mohamed Al Junaibi; Abdu Adem; Amanda J Lee, John Marsden. Effectiveness of medication management with therapeutic drug monitoring in opioid assisted treatment: a pragmatic, open-label, two-arm randomized controlled trial. Prepared for the ADDICTION
• Hesham Elarabi; Doaa Radwan; Abuelgasim elrasheed; Mansour Shawky; Nael Mustafa; Ahmed Yousif Ali; Mona Osman , Ahmed Kashmar; Helal Al Kathiri; Tarek Gawad; Ayman Kodera; Mohamed Al Junaibi; Abdu Adem; Amanda J Lee, John Marsden. Effectiveness of Buprenorphine/Naloxone and Therapeutic Drug Monitoring reduce severity on co-occurring mental health disorders and non-opioid substance use among adults with opioid use disorders. Prepared for the Drug and Alcohol Review.
• Hesham Elarabi; Mansour Shawky; Nael Mustafa; Doaa Radwan; Abuelgasim elrasheed; Ahmed Yousif Ali; Mona Osman , Ahmed Kashmar; Helal Al Kathiri; Tarek Gawad; Ayman Kodera; Mohamed Al Junaibi; Abdu Adem; Amanda J Lee, John Marsden. Cost of illness, cost-benefit and cost-effectiveness: opportunities for measurement and expanding medication assisted treatment in opioid use disorder.
• Mansour Shawky; Tarek A.Gawad, Hesham Elarabi, Abuelgasim elrashid, John Marden, Abdu Adem. A review of prescribing psychotropics in patients with opioid use disorder stabilized on buprenorphine/naloxone. Prepared for Acta psychiatrica

• July 2012 - FACSLM, Fellowship of The Academy of Clinical Science & laboratory Medicine, IRELAND
• October, 2004 - Specialty Certificate Equalized as )Clinical Doctorate) in Clinical Chemistry- 48 months –Medical University of SOFIA, Republic of Bulgaria.
• May 1985 - Bsc. Biochemistry, Alexandria University, Egypt
  
• May 2014 - Membership of The International Association of Forensic Toxicologists (TIAFT)
• Jan 2014 - Member of The American Association for Clinical Chemistry (AACC) U.S. A
• SEPT. 2013 - Member Of The International  Association Of Therapeutic Drug Monitoring & Clinical Toxicology–IATDMCS . (USA & CANADA)
• March 2010 - Fellow of The Academy of Clinical Science & laboratory Medicine, IRELAND, Membership number: 2651 Certified and licensed to practice as Clinical Chemist at all public and private Medical & Health Institutions in the republic of Ireland                                          
  
• Feb. 2009 - Certification, Licensure & Recognition Certificate of recognition of a professional qualification and specialization in the EU Member-States, European Economic Area EEA) and Switzerland , issued by the Ministry of Health in the Republic of Bulgaria
• May 2007 - Membership of the Association for Clinical Biochemistry & Laboratory Medicine , United kingdom ( G09256 )
• Oct. 2004 - Certified and licensed to practice as consultant in Clinical   Chemistry, at all public & private medical and health institutions in the Republic of Bulgaria
• Jan 2005 - Evaluated as Consultant Clinical Biochemist Ministry of Health, Abu Dhabi, UAE

Name: abuelgasim.elrasheed@nrc.gov.ae
Phone: +971 2 306 0005
Office Address: 21007 W2